Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adults with plantar heel pain¹
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic asthma
LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Duration of trials: 12 to 20 weeks · adults and adolescents with persistent asthma
The intervention probably leads to higher serious adverse events Duration of trials: 12 to 20 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review